name 5 stocks currently developing obesity drugs

Based on the conditions you provided, no matching data was found. I will try to provide a answer based on the relevant information for your reference. Here are five stocks currently developing obesity drugs: 1. <strong>Novo Nordisk</strong>: Novo Nordisk is a leading pharmaceutical company that has developed semaglutide, which is marketed as Ozempic for type 2 diabetes and as Wegovy for weight loss. 2. <strong>Eli Lilly</strong>: Eli Lilly is another major player in the obesity drug market. The company has developed tirzepatide, which is marketed as Mounjaro for type 2 diabetes and is expected to receive regulatory approval for weight loss this year. 3. <strong>Viking Therapeutics</strong>: Viking Therapeutics is a biotechnology company that is developing VK2809, an investigational obesity treatment that targets the GLP-1 pathway. 4. <strong>Pfizer</strong>: Pfizer is a multinational pharmaceutical company that is developing oral GLP-1 agonists for obesity treatment. These drugs are designed to address some of the unmet needs of current products, such as ease of manufacturing and lower cost. 5. <strong>Cantor Fitzgerald</strong>: Cantor Fitzgerald is an investment bank that covers Pfizer, one of the companies vying for a piece of the obesity drug market. The firm is tracking more than 150 studies with 78 agents in development, and analyst Louise Chen expects that there will be more companies in the space over the next decade. These stocks are just a few examples of companies that are currently developing obesity drugs. There may be other companies not mentioned here that are also working on obesity treatments.